Bridgebio Pharma Drug Patent Portfolio

Bridgebio Pharma's Family Patents


Family Patents



Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Bridgebio Pharma News

Pfizer Defends Its Leading Heart Drug as Alnylam and BridgeBio Join the Competition

22 Apr, 2025

See More